Beam Therapeutics is pioneering the use of CRISPR base editing to develop precision genetic medicines that treat disease, one letter at a time.

What is base editing?

Base editing is a new category in CRISPR gene editing. Our groundbreaking technology allows us to make specific edits to base pairs in DNA or RNA. We use the power of a CRISPR enzyme to target a single location within the genome out of billions of bases (A, C, G, T). At that site, our technology is capable of precisely editing just a single base, without cutting the DNA or RNA strands.

Who we are

We’re building a world-class team, starting with our founders and funders. Beam’s co-founders helped put CRISPR gene editing on the map, and with Beam they’re coming together again to pursue therapies for serious diseases using groundbreaking base editing technology. Our funders, F-Prime and ARCH Venture Partners, are two of the world’s leading biotech venture capital firms.

What we do

Over half of the genetic errors associated with disease result from a single-letter change in the billions of bases that form the genome. In other cases, certain natural genetic variations in DNA are known to protect against disease. By changing a single letter – to eliminate errors or write in protective changes – in enough cells, base editing may help us prevent, modify, and even cure a wide range of diseases affecting patients’ lives.


Beam was launched in 2018 with $87 million in Series A financing led by F-Prime Capital and ARCH Venture Partners. In 2019, the company completed a $135 million Series B financing from new investors Redmile Group, LLC, Cormorant Asset Management, GV, Altitude Life Science Ventures, and additional undisclosed investors, along with continued support by existing investors, including F-Prime Capital, ARCH Venture Partners, Eight Roads Ventures, and Omega Funds.


Beam has assembled the leading portfolio of base editing intellectual property across multiple foundational base editing platforms in the field of human therapeutics. We have a license agreement with Harvard University for two base editing platforms developed in David Liu’s lab. We are also able to acquire RNA base editing technologies from Feng Zhang’s lab. Finally, we have a licensing and option agreement with Editas Medicine for exclusive rights to certain intellectual property licensed to Editas Medicine by Harvard, the Broad Institute, and Massachusetts General Hospital (MGH), as well as to certain Editas Medicine technologies.